Abstract
A 65-year-old man with a 3-year history of unresectable colon cancer was switched to FOLFIRI (5-fluorouracil, levofolinate calcium, irinotecan) and panitumumab, after the failure of FOLFIRI and bevacizumab, in February 2013. After the fourth dose of panitumumab, painful eruptions rapidly developed (figures 1A-C). An autoimmune bullous disease, subcorneal pustular dermatosis and impetigo contagiosa were suspected. However, no autoantibodies against bullous pemphigoid-180, desmoglein 1,or desmoglein [...]
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
